Bailard’s Olema Pharmaceuticals OLMA Stock Holding History

Bailard’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-22,400	Closed	-$91K	–	731
2022 Q2	$91K	Buy	+22,400	New	+$71K	﹤0.01%	660

Other funds holding OLMA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Bailard's OLMA Position: Q3 2022 in Review

Bailard sold out of Olema Pharmaceuticals (OLMA) in Q3 2022, closing a stake of 22,400 shares — an estimated $91K sold.

Bailard first reported a position in OLMA in Q2 2022 and held it in 1 quarter. The position peaked at $91K in Q2 2022. 73 funds tracked by Wall St. Rank hold OLMA as of Q3 2022.

Bailard reported no remaining Olema Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Bailard sold 22,400 Olema Pharmaceuticals shares in Q3 2022, an estimated $91K.
Bailard first reported a position in Olema Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Bailard's Olema Pharmaceuticals position peaked at $91K in Q2 2022.
73 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.